ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Blood-based biomarkers in Alzheimer's disease: Future directions for implementation.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 12 citations in OpenAlex.
- Factors influencing implementation of an Alzheimer's disease blood test among UK old age psychiatrists: mixed-methods study using the theoretical domains framework.Age and ageing · 2026Article
- Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice.The journal of prevention of Alzheimer's disease · 2026Article
- Advancing Early Detection of Alzheimer Disease in the Primary Care Setting in the United States.Neurology. Clinical practice · 2026Article
- Expression differences and diagnostic efficacy of core plasma biomarkers in Alzheimer's disease, cerebral small vessel disease and healthy adults.Frontiers in neurology · 2026Article
- Recent Advances in Drug Development for Alzheimer's Disease: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations.Neurology · 2025Observational
- Perceptions about preclinical Alzheimer's disease biomarker collection procedure influences willingness to participate: Findings from an ethnoracially diverse study.Journal of Alzheimer's disease : JAD · 2025Article
- Evaluation of the diagnostic efficacy of core biomarkers in cerebrospinal fluid for Alzheimer's disease: a systematic review and meta-analysis.Frontiers in neurology · 2025Review
- Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications.Neurology and therapy · 2024Review
- Blood-Based Biomarkers in Alzheimer's Disease: Advancing Non-Invasive Diagnostics and Prognostics.International journal of molecular sciences · 2024Review
- Perceptions of the use of biomarkers for Alzheimer's disease diagnosis: A systematic review and synthesis of the qualitative literature.Alzheimer's & dementia (Amsterdam, Netherlands)Review
- Opportunities to encourage adoption of a biomarker-enabled care pathway for Alzheimer's in primary care.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- A scalable workflow using digital cognitive assessment and pTau217 for MCI detection.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Blood-based biomarkers in Alzheimer's disease: Future directions for implementation.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDisease-modifying therapies (DMTs) for Alzheimer's disease (AD) will increase diagnostic demand. A non-invasive blood-based biomarker (BBBM) test for detection of amyloid-β pathology may reduce diagnostic barriers and facilitate DMT initiation.
objectiveTo explore heterogeneity in AD care pathways and potential role of BBBM tests.
methodsSurvey of 213 healthcare professionals/payers in US/China/UK/Germany/Spain/France and two advisory boards (US/Europe).
resultsCurrent diagnostic pathways are heterogeneous, meaning many AD patients are missed while low-risk patients undergo unnecessary procedures. Confirmatory amyloid testing (cerebrospinal fluid biomarkers/positron emission tomography) is utilized in few patients, resulting in diagnostic/treatment delays. A high negative-predictive-value test could streamline the diagnostic pathway by reducing unnecessary procedures in low-risk patients; supporting confirmatory testing where needed. Imminent approval of DMTs will increase need for fast and reliable AD diagnostic tests. DISCUSSION: An easy-to-use, accurate, non-invasive BBBM test for amyloid pathology could guide diagnostic procedures or referral, streamlining early diagnosis and DMT initiation. Highlights: This study explored AD care pathways and how BBBM may meet diagnostic demandsCurrent diagnostic pathways are heterogeneous, with country and setting variationsMany AD patients are missed, while low-risk patients undergo unnecessary proceduresAn easy-to-use, accurate, non-invasive BBBM test for amyloid pathology is neededThis test could streamline early diagnosis of amyloid pathology and DMT initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.